First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers

被引：0

作者：

Thierry Landre

Gaetan Des Guetz

Kader Chouahnia

Cherifa Taleb

Alain Vergnenègre

Christos Chouaïd

机构：

[1] Hôpital René-Muret,UCOG 93

[2] APHP,Service d’Oncologie Médicale

[3] Centre Hospitalier Delafontaine,Service d’Oncologie Médicale

[4] Hôpital Avicenne,Service d’Oncogériatrie

[5] APHP,Service de Pneumologie

[6] Hôpital René-Muret,undefined

[7] APHP,undefined

[8] Service d’Oncologie Médicale,undefined

[9] Unité d’Oncologie Thoracique,undefined

[10] Centre Hospitalier Intercommunal (CHI) Créteil,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷

关键词：

Non-small-cell lung cancer; PD-L1; Anti-PD-1/PD-L1; Immunotherapy; Meta-analysis; Management; Chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：441 / 448

页数：7

共 50 条

[11] PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma
Mo, Dun-Chang
Huang, Jian-Feng
Luo, Peng-Hui
Chen, Long
Zou, Biao
Wang, Han-Lei
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2023, 280 (01) : 1 - 9
[12] Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
Xiaodi Guo
Wendong Li
Jiexuan Hu
Emily C. Zhu
Qiang Su
European Journal of Clinical Pharmacology, 2020, 76 : 1345 - 1354
[13] Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
Guo, Xiaodi
Li, Wendong
Hu, Jiexuan
Zhu, Emily C.
Su, Qiang
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (10) : 1345 - 1354
[14] PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
Jing, Wang
Li, Miaomiao
Zhang, Yan
Teng, Feifei
Han, Anqin
Kong, Li
Zhu, Hui
ONCOTARGETS AND THERAPY, 2016, 9 : 489 - 502
[15] Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China
Teng, Meng-Meng
Chen, Si-Ying
Yang, Bo
Wang, Yan
Han, Rui-Ying
An, Meng-Na
Dong, Ya-lin
You, Hai-Sheng
CANCER MEDICINE, 2021, 10 (18): : 6344 - 6353
[16] PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer
Polak, Paz
Fu, Lili
Foulkes, William D.
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (09): : 866 - 868
[17] EFFICACY OF PD1/PD-L1 INHIBITORS VS CHEMOTHERAPY AS FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER AMONG PATIENTS WITH DIFFERENT PD-L1 EXPRESSION LEVELS
Lin, G.
Lingohr-Smith, M.
Deitelzweig, C.
Lin, J.
VALUE IN HEALTH, 2022, 25 (07) : S318 - S318
[18] Conventional chemotherapy combined with PD-1/PD-L1
不详
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 (SUPPL 3) : 60 - 63
[19] Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis
Zhang, Shuang
Li, Shuang
Cheng, Ying
THORACIC CANCER, 2020, 11 (12) : 3536 - 3546
[20] PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1 negative metastatic lung adenocarcinoma: A real-world data
Ge, Yihui
Sun, Yuping
Gao, Aiqin
Li, Juan
Wang, Dahai
Wu, Jiake
Sun, Yanxin
Sun, Haifeng
Sun, Haodong
Li, Jie
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →